| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Malcolm, Karl
Queen's University Belfast
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (21/21 displayed)
- 2023A multipurpose ‘CZL’ vaginal ring for non-hormonal contraception and STI/HIV prevention
- 2021Custom silicone elastomers for improved mechanical performance and reduced hormone binding in a dapivirine/levonorgestrel vaginal ring
- 2021Preliminary formulation development of silicone elastomer vaginal rings for sustained release of metronidazole, sucrose and lactobacillus
- 2021Formulation development of an ethylene vinyl acetate ring for sustained release of the experimental entry inhibitor DS003
- 2021Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrelcitations
- 2019Dapivirine-releasing vaginal rings produced by plastic freeforming additive manufacturingcitations
- 2019Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTEScitations
- 2019Post-use ring weight, residual drug content and drug depletion zone thickness as objective measures of user adherence to a contraceptive progesterone vaginal ringcitations
- 2019Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomerscitations
- 2019Mechanical testing methods for drug-releasing vaginal ringscitations
- 2019In vitro release testing methods for drug-releasing vaginal ringscitations
- 2018Density Mediated Drug Release From Dapivirine Vaginal Rings Produced by Additive Manufacturing
- 2017Packing polymorphism of dapivirine and its impact on the performance of a dapivirine-releasing silicone elastomer vaginal ringcitations
- 2014Thermal properties and eutectic behaviour of dapivirine in combination with steroid hormones and other antiretrovirals
- 2011Dual functional ionic liquids as plasticisers and antimicrobial agents for medical polymerscitations
- 2010Development of liposome-based freeze-dried rods for vaginal vaccine delivery against HIV-1citations
- 2009Persistence of antimicrobial activity through sustained release of triclosan from pegylated silicone elastomerscitations
- 2009Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primate
- 2008The Effect of Tacticity on the Conformational Properties of Poly(1-olefin sulfone)scitations
- 2004Controlled release of a model antibacterial drug from a novel self-lubricating silicone biomaterialcitations
- 2001Determination of the drug solubility at the melt temperature in silicone intravaginal rings using dynamic mechanical analysis
Places of action
| Organizations | Location | People |
|---|
article
Post-use ring weight, residual drug content and drug depletion zone thickness as objective measures of user adherence to a contraceptive progesterone vaginal ring
Abstract
Objectives:<br/>A major challenge in the development of drug-releasing vaginal rings is the accurate and reliable measurement of adherence in clinical trials. In efforts to move away from reliance on self-reported measures of adherence, there is considerable interest in the development and testing of more objective quantitative measures. Here, we assessed post-use ring weight, residual drug content and drug depletion zone thickness as potential cumulative measures of adherence to a progesterone-releasing ring.<br/><br/>Study design:<br/>Progesterone-releasing rings (n=115) used by women across three sites in Africa were assessed for ring weight, residual progesterone content (via solvent extraction and HPLC-UV analysis), and drug depletion zone thickness (using digital microscopy) as potential measures of user adherence. <br/><br/>Results:<br/>Unused control rings (n=6) had mean progesterone content of 2058 ± 21 mg (99.2 ± 1.0 %; relative to 2074 mg nominal loading) and ring weight of 9.372 ± 0.016 g. Mean residual progesterone content and post-use ring weight for clinical rings were 1245 ± 245 mg and 8.6 ± 0.2 g, respectively. Wide variations in residual progesterone content (range 45.0–100% of controls) and ring weight (range 87.9–100.3%) of used rings were attributed to differences in extent of ring use. Linear correlations were observed between residual progesterone content and post-use ring weight (r2=0.8244), and thickness of the drug depletion zone with post-use ring weight (r2=0.9757) and residual drug content (r2=0.9743).<br/><br/>Conclusions:<br/>Post-use ring weight, residual progesterone content and depletion zone thickness are potentially useful as objective cumulative measures of adherence to a progesterone-releasing vaginal ring. <br/>